

# Carmen Chak-Lui Wong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/414620/publications.pdf>

Version: 2024-02-01

64  
papers

6,361  
citations

81839

39  
h-index

118793

62  
g-index

65  
all docs

65  
docs citations

65  
times ranked

9841  
citing authors

#	ARTICLE	IF	CITATIONS
1	Polo-like kinase 4 inhibitor CFI400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity. <i>Hepatology</i> , 2023, 77, 729-744.	3.6	16
2	Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-1. <i>Hepatology Communications</i> , 2022, 6, 178-193.	2.0	16
3	Histone chaperone FACT complex coordinates with HIF to mediate an expeditious transcription program to adapt to poorly oxygenated cancers. <i>Cell Reports</i> , 2022, 38, 110304.	2.9	6
4	Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 383-396.	1.8	36
5	Hypoxia-induced macropinocytosis represents a metabolic route for liver cancer. <i>Nature Communications</i> , 2022, 13, 954.	5.8	38
6	Role of Metabolism in Adoptive T Cell Therapy: Strategies and Challenges. <i>Antioxidants and Redox Signaling</i> , 2022, 37, 1303-1324.	2.5	1
7	RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 360-371.	1.8	30
8	Genome-wide CRISPR-Cas9 knockout library screening identified PTPMT1 in cardiolipin synthesis is crucial to survival in hypoxia in liver cancer. <i>Cell Reports</i> , 2021, 34, 108676.	2.9	30
9	Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 3684.	5.8	136
10	Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors. <i>Hepatology</i> , 2021, 74, 2264-2276.	3.6	39
11	Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. <i>Cells</i> , 2021, 10, 1715.	1.8	130
12	Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer. <i>Communications Biology</i> , 2021, 4, 888.	2.0	18
13	Adaptive and Constitutive Activations of Malic Enzymes Confer Liver Cancer Multilayered Protection Against Reactive Oxygen Species. <i>Hepatology</i> , 2021, 74, 776-796.	3.6	13
14	Cancer stem cells: advances in biology and clinical translation—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2021, 1506, 142-163.	1.8	8
15	Antioxidant supplements promote tumor formation and growth and confer drug resistance in hepatocellular carcinoma by reducing intracellular ROS and induction of TMBIM1. <i>Cell and Bioscience</i> , 2021, 11, 217.	2.1	20
16	Anti-tumour effects of PIM kinase inhibition on progression and chemoresistance of hepatocellular carcinoma. <i>Journal of Pathology</i> , 2020, 252, 65-76.	2.1	9
17	Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. <i>Gastroenterology</i> , 2020, 159, 609-623.	0.6	100
18	Hypoxia and the Metastatic Niche. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1136, 97-112.	0.8	18

#	ARTICLE	IF	CITATIONS
19	<sc>YY</sc> 1 regulates skeletal muscle regeneration through controlling metabolic reprogramming of satellite cells. EMBO Journal, 2019, 38, .	3.5	69
20	Aberrant Super-enhancer Landscape in Human Hepatocellular Carcinoma. Hepatology, 2019, 69, 2502-2517.	3.6	90
21	Assessment of Stabilization and Activity of the HIFs Important for Hypoxia-Induced Signalling in Cancer Cells. Methods in Molecular Biology, 2019, 1928, 77-99.	0.4	5
22	Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway. Cell Death and Disease, 2019, 10, 934.	2.7	98
23	Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma. Hepatology, 2019, 69, 1768-1786.	3.6	111
24	HELLS Regulates Chromatin Remodeling and Epigenetic Silencing of Multiple Tumor Suppressor Genes in Human Hepatocellular Carcinoma. Hepatology, 2019, 69, 2013-2030.	3.6	56
25	RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology, 2018, 67, 2254-2270.	3.6	980
26	Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. Oncogenesis, 2018, 7, 44.	2.1	31
27	SENPI1 promotes hypoxia-induced cancer stemness by HIF-1 $\alpha$ deSUMOylation and SENPI1/HIF-1 $\alpha$ positive feedback loop. Gut, 2017, 66, 2149-2159.	6.1	141
28	Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. Journal of Hepatology, 2017, 67, 758-769.	1.8	118
29	Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nature Communications, 2017, 8, 517.	5.8	319
30	The folate cycle is a new metabolic weakness of cancer. Molecular and Cellular Oncology, 2017, 4, e1327004.	0.3	13
31	Secretory Stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway. Cancer Letters, 2017, 403, 330-338.	3.2	37
32	Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. Journal of Clinical Investigation, 2017, 127, 1856-1872.	3.9	100
33	Hormonal control of the metabolic machinery of hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2016, 5, 195-197.	0.7	3
34	Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. Hepatology, 2016, 64, 797-813.	3.6	170
35	Down-regulation of TIMP2 by HIF-1 $\alpha$ /miR-210/HIF-1 $\alpha$ regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. Hepatology, 2016, 64, 473-487.	3.6	96
36	Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. Hepatology, 2016, 63, 474-487.	3.6	140

#	ARTICLE	IF	CITATIONS
37	NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3105-3117.	3.2	68
38	Transketolase counteracts oxidative stress to drive cancer development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E725-34.	3.3	186
39	PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 10880-10892.	0.8	55
40	MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility. <i>Frontiers of Medicine</i> , 2015, 9, 331-343.	1.5	42
41	MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. <i>Oncotarget</i> , 2015, 6, 13658-13670.	0.8	70
42	Switching of Pyruvate Kinase Isoform L to M2 Promotes Metabolic Reprogramming in Hepatocarcinogenesis. <i>PLoS ONE</i> , 2014, 9, e115036.	1.1	67
43	The impact of hypoxia in hepatocellular carcinoma metastasis. <i>Frontiers of Medicine</i> , 2014, 8, 33-41.	1.5	62
44	Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. <i>Hepatology</i> , 2014, 60, 1645-1658.	3.6	197
45	RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-Kinase/Myosin phosphatase target pathway. <i>Hepatology</i> , 2013, 57, 152-161.	3.6	42
46	Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. <i>Hepatology</i> , 2013, 57, 637-647.	3.6	90
47	Hypoxia-inducible factor-1-dependent breast cancer mesenchymal stem cell bidirectional signaling promotes metastasis. <i>Journal of Clinical Investigation</i> , 2013, 123, 189-205.	3.9	171
48	Hypoxia-inducible factor-1-dependent breast cancer mesenchymal stem cell bidirectional signaling promotes metastasis. <i>Journal of Clinical Investigation</i> , 2013, 123, 1402-1402.	3.9	137
49	EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers. <i>PLoS ONE</i> , 2013, 8, e68226.	1.1	45
50	Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2707-16.	3.3	180
51	Sequential alterations of microrna expression in hepatocellular carcinoma development and venous metastasis. <i>Hepatology</i> , 2012, 55, 1453-1461.	3.6	92
52	Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. <i>Hepatology</i> , 2012, 56, 622-631.	3.6	255
53	Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. <i>Journal of Molecular Medicine</i> , 2012, 90, 803-815.	1.7	191
54	Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16369-16374.	3.3	375

#	ARTICLE	IF	CITATIONS
55	The MicroRNA miR-139 Suppresses Metastasis and Progression of Hepatocellular Carcinoma by Down-regulating Rho-Kinase 2. <i>Gastroenterology</i> , 2011, 140, 322-331.	0.6	268
56	Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. <i>Journal of Hepatology</i> , 2011, 54, 1177-1184.	1.8	136
57	Transcriptional Repressive H3K9 and H3K27 Methylations Contribute to DNMT1-Mediated DNA Methylation Recovery. <i>PLoS ONE</i> , 2011, 6, e16702.	1.1	24
58	RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N' Rho move it. <i>Liver International</i> , 2010, 30, 642-656.	1.9	38
59	Abstract 4095: Aberrant expression of epigenetically regulated microRNAs in liver cancer. , 2010, , .		0
60	Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. <i>Hepatology</i> , 2009, 49, 1583-1594.	3.6	122
61	Identification of tumor suppressive activity by irradiation microcell-mediated chromosome transfer and involvement of $\alpha$ -crystallin in nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , 2008, 122, 1288-1296.	2.3	22
62	Deleted in Liver Cancer 1 (DLC1) Negatively Regulates Rho/ROCK/MLC Pathway in Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2008, 3, e2779.	1.1	62
63	Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. <i>Hepatology</i> , 2007, 45, 1129-1138.	3.6	93
64	RhoE/ROCK2 regulates chemoresistance through NF- $\kappa$ B/IL-6/ STAT3 signaling in hepatocellular carcinoma. <i>Oncotarget</i> , 0, 7, 41445-41459.	0.8	30